798577-91-0

Usage

Uses

Used in Oncology:
BAL27862 is used as an anti-cancer agent for its ability to inhibit the activity of various kinases involved in cancer cell growth and proliferation. It has been studied in various cancer types, including ovarian, breast, and lung cancers, and has shown promising results in preclinical and early clinical trials.
Used in Advanced Solid Tumors and Hematologic Malignancies:
BAL27862 is used as a potential treatment for advanced solid tumors and hematologic malignancies due to its multi-targeted kinase inhibition properties. It is currently being investigated for its efficacy and safety in these areas, with the aim of providing a new therapeutic option for patients with these conditions.

Upstream product

• 72531-10-3 4-<<(benzyloxy)carbonyl>amino>acetophenone 
• 4414-74-8 2-(1H-benzo[d]imidazol-1-yl)acetonitrile 
• 99-92-3 p-aminobenzophenone 
• 157014-41-0 4-((carbobenzyloxy)amino)phenacyl bromide 
• 798578-48-0 3-{[4-(1H-benzoimidazol-2-yl)-1,2,5-oxadiazol-3-yl]amino}propanenitrile 
• 332026-86-5 3-amino-4-(1H-benzo[d]imidazol-2-yl)-1,2,5-oxadiazole 
• 63823-75-6 α-hydroxyimino-(1H-benzimidazol-2-yl) acetonitrile 
• 1263384-50-4 [4-(2-{2-[4-(2-cyano-ethylamino)furazan-3-yl]benzoimidazol-1-yl}acetyl)phenyl]carbamic acid benzyl ester 

Relevant academic research and scientific papers

FURAZANOBENZIMIDAZOLES AS PRODRUGS TO TREAT NEOPLASTIC OR AUTOIMMUNE DISEASES

A compound of formula (II) wherein (a) represents a divalent benzene residue which is unsubstituted or substituted by one or two additional substituents independently selected from lower alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino, mono(lower alkyl)amino, di(lower alkyl)amino, mono(lower alkenyl)amino, di(lower alkenyl)amino, lower alkoxycarbonylamino, lower alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form together with the nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower 15 alkoxycarbonyl, cyano, halogen, and nitro; or wherein two adjacent substituents can be methylenedioxy; or a divalent pyridine residue (Z = N) which is unsubstituted or substituted additionally by lower alkyl, lower alkoxy, lower alkoxy-lower alkoxy,amino, optionally substituted by one or two substituents selected from lower alkyl, lower alkenyl and alkylcarbonyl, halo-20 lower alkyl, lower alkoxy-lower alkyl, or halogen; R1 represents hydrogen, lower alkylcarbonyl, hydroxy-lower alkylor cyano-loweralkyl; and R2 represents a group selected from: (b), (c) and (d); or pharmaceutically acceptable salts thereof.

FURAZANOBENZIMIDAZOLES

The invention relates to compounds of formula (I) wherein R represents aryl or heteroaryl, X is oxygen, a carbonyl group, an oxime derivative of a carbonyl group or an α,?-unsaturated carbonyl group, and the substituents R1 to R6 have the meanings given in the specification, for use as medicaments, to novel compounds of formula (I), to methods of synthesis of such compounds, to pharmaceutical compositions containing compounds of formula (I), to the use of a compounds of formula (I) for the preparation of a pharmaceutical composition for the treatment of neoplastic and autoimmune diseases, and to methods of treatment of neoplastic and autoimmune diseases using such compounds of formula (I) or of pharmaceutical compositions containing same.